In this episode, Our guest host Avromi talks about pushing GDMT via the STRONG-HF trial. We also start our MHP2023 recap series with some pearls from Dr. Zier's cardiology update session.

| 00.33 - TOC |

| 01.19 - MHP2023 Afib updates |

• AFFIRM 2002 (rate and rhythm non-inferior)
• EAST-AFNET 4 - using dofetilide
• CABANA - using ablation and evaluating HF patients
• ESC commentary - impact of AFFIRM and changes in management to today

| 03.04 - Guest host Avromi and STRONG-HF [Lancet 2022]. Click here for a slide deck overview of the study. |

| 08.49 - MHP2023 high-sensitivity Troponin and AMI management |

• COMPASS-MI - using hs-cTnT for early rule out
• PLATO (lower primary outcome w/ ticagrelor v clopidogrel, equivalent bleeding), TRITON-TIMI 38 (lower primary outcome w/ prasugrel v clopidogrel, equivalent bleeding), ISAR-REACT 5 (lower mortality w/prasugrel v ticagrelor w/ similar bleeding risks)
• RAPID CABG (NOT PEER REVIEWED YET)- similar rates of bleeding waiting off ticagrelor 2-3d vs 5-7d
• REVERSE-IT - bentracimab for reversal of ticagrelor
• 2023 ESC Guidelines for ACS

| 11.17 - Closing |

[The appearance of external hyperlinks does not constitute endorsements by UCSF of the linked websites, or the information, products, or services contained therein. UCSF does not exercise any editorial control over the information found therein, nor does UCSF make any representation of their accuracy or completeness. All information contained in this episode are the opinions of the respective speakers and not necessarily the views their respective institutions or UCSF, and is only provided for information purposes, not to diagnose or treat.]

png image from pngtree.com